Bodansky A, Mettelman R, Sabatino Jr J, Vazquez S, Chou J, Novak T
Nature. 2024; 632(8025):622-629.
PMID: 39112696
PMC: 11324515.
DOI: 10.1038/s41586-024-07722-4.
Stake J, Spiekers C, Akkurt B, Heindel W, Brix T, Mannil M
Diagnostics (Basel). 2024; 14(11).
PMID: 38893597
PMC: 11171889.
DOI: 10.3390/diagnostics14111070.
Saito Y, Yang Y, Saito M, Park C, Funato K, Tabar V
Proc Natl Acad Sci U S A. 2024; 121(10):e2314695121.
PMID: 38416679
PMC: 10927500.
DOI: 10.1073/pnas.2314695121.
Joy S, Agarwal A, Shamim S, Garg A
BMJ Case Rep. 2023; 16(9).
PMID: 37696607
PMC: 10496712.
DOI: 10.1136/bcr-2022-254397.
Fortunato F, Giugno A, Sammarra I, Labate A, Gambardella A
Curr Neuropharmacol. 2022; 21(8):1714-1735.
PMID: 35794773
PMC: 10514543.
DOI: 10.2174/1570159X20666220706094651.
A Breakdown of Immune Tolerance in the Cerebellum.
Hampe C, Mitoma H
Brain Sci. 2022; 12(3).
PMID: 35326284
PMC: 8946792.
DOI: 10.3390/brainsci12030328.
Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity.
Panja D, Vedeler C, Schubert M
Neuropathol Appl Neurobiol. 2018; 45(2):141-156.
PMID: 29679372
PMC: 7379599.
DOI: 10.1111/nan.12492.
Detection of brain-directed autoantibodies in the serum of non-small cell lung cancer patients.
Banjara M, Ghosh C, Dadas A, Mazzone P, Janigro D
PLoS One. 2017; 12(7):e0181409.
PMID: 28746384
PMC: 5528996.
DOI: 10.1371/journal.pone.0181409.
Proteolytic degradation and potential role of onconeural protein cdr2 in neurodegeneration.
Hwang J, Lee J, Oh C, Kang H, Hwang I, Um J
Cell Death Dis. 2016; 7(6):e2240.
PMID: 27253404
PMC: 5143381.
DOI: 10.1038/cddis.2016.151.
A destructive feedback loop mediated by CXCL10 in central nervous system inflammatory disease.
Roberts W, Blachere N, Frank M, Dousmanis A, Ransohoff R, Darnell R
Ann Neurol. 2015; 78(4):619-29.
PMID: 26224283
PMC: 4583819.
DOI: 10.1002/ana.24494.
Paving the Way to Understand Autoantibody-Mediated Epilepsy on the Molecular Level.
Seebohm G, Piccini I, Strutz-Seebohm N
Front Neurol. 2015; 6:149.
PMID: 26217297
PMC: 4491625.
DOI: 10.3389/fneur.2015.00149.
Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis.
Schubert M, Panja D, Haugen M, Bramham C, Vedeler C
Acta Neuropathol. 2014; 128(6):835-52.
PMID: 25341622
PMC: 4231287.
DOI: 10.1007/s00401-014-1351-6.
A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes.
de Jongste A, van Gelder T, Bromberg J, de Graaf M, Gratama J, Schreurs M
Neuro Oncol. 2014; 17(1):145-50.
PMID: 24994790
PMC: 4483045.
DOI: 10.1093/neuonc/nou126.
Modulator of Apoptosis 1: A Highly Regulated RASSF1A-Interacting BH3-Like Protein.
Law J, Yu V, Baksh S
Mol Biol Int. 2012; 2012:536802.
PMID: 22745908
PMC: 3382356.
DOI: 10.1155/2012/536802.
Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies.
de Jongste A, de Graaf M, Martinuzzi E, van den Broek P, Kraan J, Lamers C
Neuro Oncol. 2012; 14(7):841-8.
PMID: 22591661
PMC: 3379804.
DOI: 10.1093/neuonc/nos118.
Encephalitis with herpes simplex-2 in the cerebrospinal fluid and anti-RI (ANNA-2) antibodies: an infectious or a paraneoplastic syndrome?.
Novy J, Carota A, Eggimann P, Pusztaszeri M, Rossetti A, Du Pasquier R
BMJ Case Rep. 2011; 2009.
PMID: 21833342
PMC: 3029830.
DOI: 10.1136/bcr.12.2008.1363.
RNA regulation in neurologic disease and cancer.
Darnell R
Cancer Res Treat. 2010; 42(3):125-9.
PMID: 20948916
PMC: 2953774.
DOI: 10.4143/crt.2010.42.3.125.
The onconeural antigen cdr2 is a novel APC/C target that acts in mitosis to regulate c-myc target genes in mammalian tumor cells.
ODonovan K, Diedler J, Couture G, Fak J, Darnell R
PLoS One. 2010; 5(4):e10045.
PMID: 20383333
PMC: 2850929.
DOI: 10.1371/journal.pone.0010045.
Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells.
Roberts W, DeLuca I, Thomas A, Fak J, Williams T, Buckley N
J Clin Invest. 2009; 119(7):2042-51.
PMID: 19509467
PMC: 2701858.
DOI: 10.1172/JCI36131.
CRMP5 antibodies in patients with small-cell lung cancer or thymoma.
Monstad S, Drivsholm L, Skeie G, Aarseth J, Vedeler C
Cancer Immunol Immunother. 2007; 57(2):227-32.
PMID: 17657489
PMC: 11030797.
DOI: 10.1007/s00262-007-0369-1.